Owen Wallace's most recent trade in Monte Rosa Therapeutics Inc was a trade of 119,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 2, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 119,000 | 119,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 117,450 | 117,450 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 387,069 | 387,069 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 113,298 | 113,298 | - | - | Stock Option (Right to Buy) | |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2020 | 6,350 | 75,592 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 14 Sep 2020 | 6,350 | 133,438 (0%) | 0% | 7.8 | 49,784 | Common Stock |